Trials / Active Not Recruiting
Active Not RecruitingNCT04696809
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teclistamab | Teclistamab will be administered subcutaneously. |
Timeline
- Start date
- 2021-02-22
- Primary completion
- 2026-04-22
- Completion
- 2026-04-22
- First posted
- 2021-01-06
- Last updated
- 2026-04-13
Locations
15 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04696809. Inclusion in this directory is not an endorsement.